COMMENT: Speedier US FDA calls for new business strategies
This article was originally published in Clinica
Executive Summary
New measures to streamline and accelerate the US FDA approval process appear to be bearing fruit. Companies should now rethink their business strategy, write Ken West, Dennis Burns and Reinhard Merz of US consultancy TCG